Who
Bryan Giraudo
COO/CFO
Company insider
Files Form 4 as: COO/CFO, Gossamer Bio; Director, Protagonist Therapeutics.
In numbers
- Trades disclosed
- 125
- Buys
- 12
- Sells
- 5
- Bought
- $675K
- Sold
- $12.0M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 16 May 2017
- Last trade
- 24 Aug 2026
- Last filed
- 26 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $25K25 at $1,000.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | $25K25 at $1,000.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —5,800,051 at $0.00 | filing |
| 8 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $600K6,000 at $100.00 | filing |
| 8 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $513K5,130 at $100.00 | filing |
| 8 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $600K6,000 at $100.00 | filing |
| 8 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $513K5,130 at $100.00 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $155K24,000 at $6.45 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $84K12,000 at $6.98 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $3.6M36,000 at $100.14 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M12,000 at $100.07 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $155K24,000 at $6.45 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $84K12,000 at $6.98 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $3.6M36,000 at $100.14 | filing |
| 7 May 2026filed 11 May 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M12,000 at $100.07 | filing |
News
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to BuyPTGX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Bryan Giraudo; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.